Cardiothoracic & vascular anesthesia
The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials*
Pooled result · IL-6Result — go to the resultMean difference −5.98 pg/mL 95% CI −30.44 to 18.48Authors' conclusion
The use of CytoSorb hemoadsorption in a mixed population of critically ill patients with hyperinflammatory conditions does not exhibit a consistent decrease in IL-6 and other inflammatory parameters within the first 5 days of treatment.
Study context
- Population
- Critically ill patients with hyperinflammatory conditions (7 trials medical ICU, 10 complex cardiovascular surgery under CPB)
- Participants
- 855 patients · 17 RCTs
- Comparison
- CytoSorb hemoadsorption vs control
- Outcome
- IL-6
- Follow-up
- 1 day after initiation of therapy
Methodological detailsrandom-effects model, 14 trials with notable concern about conflicts of interest, Certainty of evidence low to very low
- Random-effects model
- 14 trials with notable concern about conflicts of interest
- Certainty of evidence low to very low
Pooled result
As reported in the abstract
1 day
Mean difference
−5.98 pg/mL
95% CI −30.44 to 18.48
CytoSorb vs Control
mean difference −5.98 pg/mL (95% CI −30.44 to 18.48)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Mortality at latest follow-upHigher mortality with CytoSorb | 1.22 (1.02–1.45) | |
| 0.512Relative risk (log scale) |
IL-6 at 2, 3 and 5 days; procalcitonin
- Not lower with CytoSorb
C-reactive protein at 1, 2 and 3 days
- Not lower with CytoSorb
Mortality at 30 days
- Higher mortality with CytoSorb
Original publication
The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials*. Crit Care Med. Published 21 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →